Longitudinal outcome of Parkinson's disease patients with psychosis

被引:157
作者
Factor, SA
Feustel, PJ
Friedman, JH
Comella, CL
Goetz, CG
Kurlan, R
Parsa, M
Pfeiffer, R
机构
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[3] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
关键词
D O I
10.1212/01.WNL.0000068010.82167.CF
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: To examine the long-term outcome of PD patients with psychosis requiring antipsychotic therapy; to explore predictors of mortality, nursing home placement, dementia, and persistent psychosis; and to compare outcomes of those with persistent psychosis vs those whose psychosis resolved. Methods: Baseline data available from 59 patients enrolled in the PSYCLOPS (PSychosis and CLOzapine in PD Study) trial included age, age at onset of PD, duration of PD and psychosis, character of psychosis, medications, living setting, and scores for Mini-Mental State Examination (MMSE), Unified Parkinson's Disease Rating Scale, Hoehn and Yahr Scale, and Clinical Global Impression Scale. Longitudinal data were collected 26 months later regarding four outcomes: death, nursing home placement, diagnosis of dementia, and persistence of psychosis. Logistic regression was used to explore whether any baseline characteristics were associated with an increased likelihood of one of these outcomes. Results: At baseline, 56% of patients had an MMSE score of <25, 12% were in a nursing home, 95% had hallucinations, and 60% had paranoia. On follow-up, 25% were dead, nursing home placement occurred in 42%, psychosis was persistent in 69%, and dementia was diagnosed in 68%. Select baseline characteristics predicted individual outcomes: Nursing home placement was associated with the presence of paranoia and older age; persistent psychosis was associated with younger age at onset of PD and longer disease duration; dementia was associated with older age at PD onset and lower initial MMSE score; no characteristics predicted death. Whether psychosis persisted or not had no significant effect on the development of the other three outcomes. The prevalence of hallucinations at follow-up was not different between groups currently receiving antipsychotics vs those on no treatment. Conclusions: Psychosis in PD requiring antipsychotic therapy is frequently associated with death, nursing home placement, development and progression of dementia, and persistence of psychosis. Still, it appears the prognosis has improved with atypical antipsychotic therapy based on the finding that 28% of NH patients died within 2 years compared with 100% in a previous study done prior to availability of this treatment.
引用
收藏
页码:1756 / 1761
页数:6
相关论文
共 29 条
[1]   Prevalence and clinical correlates of psychotic symptoms in Parkinson disease - A community-based study [J].
Aarsland, D ;
Larsen, JP ;
Cummings, JL ;
Laake, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (05) :595-601
[2]   Visual hallucinations in Parkinson's disease: a review and phenomenological survey [J].
Barnes, J ;
David, AS .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (06) :727-733
[3]   Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease [J].
Breier, A ;
Sutton, VK ;
Feldman, PD ;
Kadam, DL ;
Ferchland, I ;
Wright, P ;
Friedman, JH .
BIOLOGICAL PSYCHIATRY, 2002, 52 (05) :438-445
[4]  
CARTER JH, 2002, PARKINSONS DIS DIAGN, P627
[5]   Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease [J].
Dewey, RB ;
O'Suilleabhain, PE .
NEUROLOGY, 2000, 55 (11) :1753-1754
[6]   Clozapine and risperidone treatment of psychosis in Parkinson's disease [J].
Ellis, T ;
Cudkowicz, ME ;
Sexton, PM ;
Growdon, JH .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2000, 12 (03) :364-369
[7]  
Factor S A, 1995, Adv Neurol, V65, P115
[8]   SLEEP DISORDERS AND SLEEP EFFECT IN PARKINSONS-DISEASE [J].
FACTOR, SA ;
MCALARNEY, T ;
SANCHEZRAMOS, JR ;
WEINER, WJ .
MOVEMENT DISORDERS, 1990, 5 (04) :280-285
[9]  
Factor SA, 2001, MOVEMENT DISORD, V16, P135, DOI 10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO
[10]  
2-Q